Skip to main content
. 2022 Feb 21;2022:9557859. doi: 10.1155/2022/9557859

Figure 2.

Figure 2

hsa-miR-582-5p directly binds to TUG1 and 3′-UTR of Siglec-15. (a) The intersection of predicted miRNAs targeting TUG1 and Siglec-15. Relative luciferase activity of dual-luciferase assay in miRNAs screen targeting (b) Siglec-15 and (c) TUG1. The coexpression relationship between hsa-miR-582-5p and (d) Siglec-15 or (e) TUG1 in clinical data from TCGA database. (f) The predicted binding sequence between hsa-miR-582-5p and TUG1 or Siglec-15. Relative luciferase activity of dual-luciferase assay in hsa-miR-582-5p targeting (g) Siglec-15 and (h) TUG1. (i) RIP assay in Hep3B cells coprecipitated with AGO2 protein. (j) RNA pull-down assay in Hep3B cells coprecipitated with biotin-labeled hsa-miR-582-5p. (k) Relative luciferase activity of dual-luciferase assay in hsa-miR-582-5p targeting Siglec-15 with TUG1 regulation. The data are presented as the means ± SD, n = 3 replicates in (b, c, and g–k). ∗P < 0.05, ∗∗P < 0.01, ∗∗∗P < 0.005. S15: Siglec-15.